Biocon
#2676
Rank
$5.11B
Marketcap
India
Country
Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. (Founder & Exec. Chairperson)
Mr. Siddharth Mittal BCom, CA, CPA (MD, CEO & Director)
Mr. Indranil Sen (Chief Financial Officer)
Summary
History
Biocon was founded in 1978 with Rs.10,000 as the initial capital.
1979 - Becomes the first Indian company to manufacture and export enzymes to the US and Europe.
1989 - Unilever acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.
1994 - Establishes Syngene International Pvt. Ltd. as a Custom Research Company .
1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.
2001 - Becomes the first Indian company to be approved by USFDA for the manufacture of lovastatin; PlaFractor is granted a US 2001 and worldwide patent.
2003 - Biocon becomes the first company worldwide to develop human insulin on a Pichia expression system.
2006 - BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and Dr. APJ Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park".
* 2008 - Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.
2009 - Syngene-Bristol Myers Squibb research facility is established in Bengaluru.
2009 - Mylan announces strategic collaboration with Biocon to Enter the Global Generic Biologics Market.
2010 - Biocon expands to Malaysia, biopharmaceutical manufacturing and R&D facility established in Iskandar Malaysia, Johor.
2011 - Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device.
2012 - Abbott announces collaboration with Syngene to Open First Nutrition R&D Center in India.
2013 - Biocon launches biologic drug ALZUMAb to treat psoriasis.
2014 - Biocon launches world's first biosimilar drug CANMAb to treat breast cancer.
2015 - Biocon launches hepatitis-C drug in India under brand name CIMIVIR-L.
2016 - Becomes the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.
2016 - Syngene sets up Amgen R&D center in Bangalore.
2017 - Biocon's Insugen is the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.
2017 - USFDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin.
2018 - Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.
2021 - Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involves Bicocon selling 15% of its biologics subsidiary to Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.
2022 - Biocon Biologics buys the biosimilar assets of Viatris, for $3.34 billion.
Mission
Vision
Key Team
Ms. Seema Shah Ahuja BA, MBA (Global Head of Communications & Corp. Brand)
S. Vijaya Kumar (Head of Operations)
Mr. Saurabh Paliwal (Head of Investor Relations)
Mr. Amitava Saha (Chief HR Officer)
Mr. Mayank Verma (Company Sec. & Compliance Officer)
Mr. Sandeep Rao M.Sc., PGDM (Sr. VP)
Dr. A. V. Sriram (Head of Quality)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. (Founder & Exec. Chairperson)
Mr. Siddharth Mittal BCom, CA, CPA (MD, CEO & Director)
Mr. Indranil Sen (Chief Financial Officer)